Fig. 7From: Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunityAge is a predictor for anti-PD-1/anti-CTLA4 therapy associated Immune-checkpoint hepatitis. A ROC analysis using age as discriminator for therapy induced hepatitis the pooled cohort (n = 106). B ROC analysis using age as discriminator for tumor response in 3 months in the total cohort of n = 94 patients whose response was assessable. Treatment response was either defined by objective response (CR + PR) (left) or disease control (CR + PR + SD) (right)Back to article page